Christin Melton, ELS

There is an unmet need for mental health interventions that address illness-related issues affecting youth with rheumatologic conditions.

Lisa Waddell, PhD, discusses new recommendations for evaluating patients suspected of having Lyme disease.

Patients with HCV are at risk for several extrahepatic sequelae. Find out what they are, and the new treatment options for managing HCV in RA.

Preliminary findings suggest that the OMERACT flare assessment tool is effective for identifying RA flares, with high agreement between providers and patients on flare status.

ICER found TIMs to be efficacious overall but did not find them to be cost-effective.

Janus kinase and signal transducers and activators of transcription inhibitors represent promising treatment targets in RA.

Researchers have long been interested in whether omega-3 supplements can improve rheumatoid arthritis symptoms.

Research emphasizes that fibromyalgia assessments should cover 6 domains: pain, comorbidities, affective vulnerability (emotional response), beliefs and attitudes, behavior, and environmental/social factors.

The growing use of expensive biologics has led public and private insurers in the United States to impose cost-sharing burdens that place these drugs out of reach for many patients. The FDA is anticipating a marked increase in the biosimilar market as more patents expire for brand-name biologics.

A review examines neuropsychiatric manifestations associated with rheumatoid arthritis.